 A new drug for patients with early Alzheimer's disease now has FDA approval. Clinical studies found that Kasunla did not reverse, but rather slowed cognitive decline. The drug clears clumps of protein linked with Alzheimer's disease from the brain after MRI scans show the clumps are gone. The once every four weeks infusion of Kasunla can be stopped. The drug's maker, Eli Lilly, says one year of treatments would cost $32,000.